Reynolds Consumer Products reported Q3 revenue and adjusted earnings per share above analyst expectations, leading to a 4.3% increase in its stock price. The company offset declines in sales volume with strong pricing power, though profitability was challenged by higher input costs and segment deleveraging. Management lowered full-year revenue guidance by 1-3% but raised the midpoint for adjusted net income to $338.5 million and expects EBITDA between $660 million and $675 million. Despite some valuation concerns, the stock remains attractive due to ongoing growth initiatives and reasonable absolute valuation.
Reynolds Consumer Products provides context for consumer staples with Pluang data as of Nov 05, 2026 13:21 WIB. Among 63 US consumer staples stocks on Pluang, 51 rose and 10 fell. Notable movers include COCO at USD 66.73 with an 11.79% increase and 99% sell order activity, DLTR at USD 145.46 up 8.50% with 100% buy orders, and AGRO at USD 8.77 down 7.78% with 100% buy orders. Typical hold times range from 13 to 59 days.
Futu Holdings Limited will announce its financial results for the third quarter ending September 30, 2026, on November 19 before U.S. market open. The company will host a live earnings conference call at 7:30 AM ET (8:30 PM Beijing/Hong Kong time) th...
Lorenz Snacks has introduced a fleet of four autonomous, electric vehicles from Einride at its production site in Neunburg vorm Wald, Germany. These vehicles will handle in-plant transport of goods and materials, replacing diesel trucks and significa...
UBS Group AG notified Bang & Olufsen A/S that its shareholding and voting rights exceeded 5% as of October 30, 2026, but fell below 5% by November 2, 2026. As of November 2, UBS held 4.66% of Bang & Olufsen's total shares and voting rights. This chan...
T-Therapeutics secured $133 million in an oversubscribed Series B funding round led by Advent Life Sciences and British Business Bank to develop its first-in-class TCR-CD3 bispecific therapies targeting cancer and autoimmune diseases. The funds will ...
Siemens Healthineers has begun separating its in vitro diagnostics business into a standalone company named Olyrian Diagnostics, expected to complete by mid-2028. This move aims to give the diagnostics unit a distinct market presence while continuing...
